Henan Lingrui Pharmaceutical Co Ltd (600285) - Total Liabilities
Based on the latest financial reports, Henan Lingrui Pharmaceutical Co Ltd (600285) has total liabilities worth CN¥2.28 Billion CNY (≈ $333.69 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Henan Lingrui Pharmaceutical Co Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Henan Lingrui Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Henan Lingrui Pharmaceutical Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Henan Lingrui Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Henan Lingrui Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Bromake New Material Co. Ltd. A
SHE:301387
|
China | CN¥913.29 Million |
|
Three's Company Media Group Co Ltd
SHG:605168
|
China | CN¥1.64 Billion |
|
Chongqing Three Gorges Water Conservancy and Electric Power Co Ltd
SHG:600116
|
China | CN¥14.50 Billion |
|
Neinor Homes SLU
MC:HOME
|
Spain | €2.55 Billion |
|
Pebblebrook Hotel Trust
NYSE:PEB
|
USA | $2.77 Billion |
|
CBIZ Inc
NYSE:CBZ
|
USA | $2.74 Billion |
|
Aether Industries Limited
NSE:AETHER
|
India | Rs7.46 Billion |
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
China | CN¥5.41 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Henan Lingrui Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600285 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Henan Lingrui Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Henan Lingrui Pharmaceutical Co Ltd (1997–2025)
The table below shows the annual total liabilities of Henan Lingrui Pharmaceutical Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.20 Billion ≈ $321.87 Million |
+13.58% |
| 2024-12-31 | CN¥1.94 Billion ≈ $283.38 Million |
-1.86% |
| 2023-12-31 | CN¥1.97 Billion ≈ $288.74 Million |
+10.49% |
| 2022-12-31 | CN¥1.79 Billion ≈ $261.34 Million |
+18.55% |
| 2021-12-31 | CN¥1.51 Billion ≈ $220.45 Million |
+32.66% |
| 2020-12-31 | CN¥1.14 Billion ≈ $166.17 Million |
+3.68% |
| 2019-12-31 | CN¥1.10 Billion ≈ $160.28 Million |
+7.86% |
| 2018-12-31 | CN¥1.02 Billion ≈ $148.60 Million |
-7.98% |
| 2017-12-31 | CN¥1.10 Billion ≈ $161.48 Million |
+26.94% |
| 2016-12-31 | CN¥869.35 Million ≈ $127.21 Million |
-11.70% |
| 2015-12-31 | CN¥984.58 Million ≈ $144.07 Million |
+7.76% |
| 2014-12-31 | CN¥913.70 Million ≈ $133.70 Million |
+37.76% |
| 2013-12-31 | CN¥663.24 Million ≈ $97.05 Million |
+11.03% |
| 2012-12-31 | CN¥597.36 Million ≈ $87.41 Million |
+14.00% |
| 2011-12-31 | CN¥524.02 Million ≈ $76.68 Million |
+7.11% |
| 2010-12-31 | CN¥489.25 Million ≈ $71.59 Million |
+29.25% |
| 2009-12-31 | CN¥378.52 Million ≈ $55.39 Million |
-9.56% |
| 2008-12-31 | CN¥418.55 Million ≈ $61.25 Million |
+15.21% |
| 2007-12-31 | CN¥363.31 Million ≈ $53.16 Million |
-7.33% |
| 2006-12-31 | CN¥392.03 Million ≈ $57.37 Million |
-0.10% |
| 2005-12-31 | CN¥392.44 Million ≈ $57.43 Million |
+9.21% |
| 2004-12-31 | CN¥359.36 Million ≈ $52.59 Million |
+24.07% |
| 2003-12-31 | CN¥289.65 Million ≈ $42.38 Million |
+3.08% |
| 2002-12-31 | CN¥281.00 Million ≈ $41.12 Million |
+77.19% |
| 2001-12-31 | CN¥158.59 Million ≈ $23.21 Million |
+49.15% |
| 2000-12-31 | CN¥106.33 Million ≈ $15.56 Million |
-5.85% |
| 1999-12-31 | CN¥112.94 Million ≈ $16.53 Million |
+49.04% |
| 1998-12-31 | CN¥75.78 Million ≈ $11.09 Million |
+36.02% |
| 1997-12-31 | CN¥55.71 Million ≈ $8.15 Million |
-- |
About Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orth… Read more